ANNUAL REPORT » COMMS & ADVOCACY » SLOANE

Problem

GenAI platforms are rapidly changing how patients, physicians, and media surface health information, with generative traffic growing 165 times faster than organic search since January 2024. For a leading pharmaceutical company preparing to release Phase II data for its GLP-1 asset, this shift created risk: traditional search and media strategies were no longer sufficient to control brand and product visibility within AI-generated responses. The company needed a data-driven approach to understand how its therapy, clinical results, and reputation were represented across emerging generative engines—and how that visibility compared to competitors. 

Solution

Sloane partnered with the in-house team to design and implement a generative engine strategy tailored to the Phase II data launch, optimizing content and media engagement for platforms including ChatGPT, Perplexity AI, and Microsoft Copilot. The team conducted a comprehensive audit of drug and manufacturer visibility across AI-generated results, benchmarked competitive share-of-voice, and analyzed how clinical trial outcomes, efficacy claims, and brand reputation were synthesized in responses. Insights from this analysis informed targeted media outreach and content refinement to strengthen inclusion and accuracy within high-influence generative outputs. 

Outcome

The brand achieved a 79% increase in overall visibility score and a 78% rise in share-of-voice across generative platforms. Drug visibility in GLP-1–related AI searches increased 3.5%, up from under 2% pre-launch. The work positioned the company to capture value in a channel expanding 165 times faster than traditional organic search, with measurable gains in relevance across priority clinical and brand content categories.